Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension

Abstract

We confirm improved survival with PAH-targeted therapies. Survival is still poor and early treatment escalation frequently needed. First-line combination therapy may more potently improve haemodynamics. MRAP/CI may represent a new prognostic marker in PAH.